Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06207396
Other study ID # ONZ-2023-0004
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date April 1, 2023
Est. completion date March 31, 2025

Study information

Verified date January 2024
Source University Hospital, Ghent
Contact Cathelijne Lyphout, MD
Phone 093322111
Email cathelijne.lyphout@uzgent.be
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study aims to document the incidence and characteristics of spiking in the Ghent region, both anamnestically and by toxicological analysis. Spiking will be analyzed by immunoassay testing and high-resolution screening according to the protocol in the laboratory of UZ Gent;


Description:

This study aims at objectivating and characterizing the patients with alleged spiking in the city of Ghent. Every patient who presents at one of the four (out of four) emergency departments of Ghent, with a suspicion of spiking (drink/food/needle-spiking included), will be offered to take part of this study. The study entails a list of questions for the patient regarding demographics, recent own medication/drug/alcohol use and experienced symptoms; whilst the caregiver (doctor/nurse) completes a questionnaire regarding symptoms at time of presentation. For a presentation within 48h after event, both blood and urine samples are requested from the patient. When presenting between 48h and 96h after the event, only urine samples are requested. On this samples, IA and LC-GCMS according to the UNODOC standards ("Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts") to objectify exogenous products. On request of the patient, these results can be added to the medical file of the patient.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date March 31, 2025
Est. primary completion date March 31, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - >18 years - Patient self-reports suspicion of spiking OR there is a suspicion of spiking by physician, police, paramedics or patient's companions - willingness to provide urine and/or blood samples (depending on timing after event) Exclusion Criteria: - Reporting more than 5 days after spiking - Unable to reliably complete the questionnaire (can be after clinical observation/recovery). - Not declaring proficiency in the language in which informed consent is offered (Dutch/English). - Not agreeing to the informed consent. - Do not consent to blood and urine collection and/or analysis. - There is a suspicion of Drug Facilitated Sexual Assault (to be referred to Care Center Sexual Violence, ZSG, where parallel study is ongoing).

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
serum and urine analysis
Spiking will be analyzed by immunoassay testing and high-resolution screening

Locations

Country Name City State
Belgium AZ Maria Middelares Gent
Belgium Spoedgevallendienst Gent
Belgium Spoedgevallendienst AZ Jan Palfijn Gent
Belgium Spoedgevallendienst AZ St. Lucas Gent

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Ghent

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary What is the incidence of spiking in adult patients presenting to the emergency departments of the four Ghent hospitals with suspected spiking? Number of patients presenting to the ED with spiking 19 months
Primary What is the type of product and mode of administration used in spiking Defining type of products and mode of administration 19 months
Primary What are patient characteristics of patients with spiking Demographic features of the patients diagnosed with spiking 19 months
Primary In what type of places does spiking occur in Ghent Location of spiking event 19 months
See also
  Status Clinical Trial Phase
Completed NCT02305004 - Blood Serum Concentrations of Routine Drugs in Patients Treated in the Intensive Care Unit.
Recruiting NCT04152096 - Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Burns Phase 4
Completed NCT03771170 - Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Peritonitis Phase 4
Completed NCT00559819 - Validation of Driving Simulator to Blood Alcohol Concentration Standards for Impaired Driving Phase 3
Completed NCT03726632 - Causality of Poisoning of the Elderly: Prospective Study Based on Data From the Poison Control Centre of Bordeaux